Bio-Rad Announces The Appointment Of New Board Member
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO.B), a global provider of life science research and clinical diagnostics products, announced today that Joel McComb has been appointed to its Board of Directors.
Mr. McComb has 25 years of life science and diagnostics business experience. Since mid-2010 he founded three technology companies in the life science and diagnostics markets under the umbrella of Point Break Capital. The technologies focus on RNA expression, cancer profiling, and pathology.
Mr. McComb served as Vice President and General Manager of Illumina, Inc.'s Life Science Business Unit, where he was responsible for leading global product development, business strategy, and overall operations. Prior to joining Illumina, from 2004 through 2008 Mr. McComb held two high level positions at General Electric, serving as President, GE Healthcare Life Sciences-Discovery Systems, and later as President, GE Healthcare, Interventional Medicine.
From 2001 through 2004 Mr. McComb was President, CEO, and on the board of Innovadyne Technologies, Inc. Prior to this, Mr. McComb held a series of executive, product development, business and sales positions at Beckman Coulter, Inc.
"We are pleased to welcome Joel to our Board of Directors," said Norman Schwartz, Bio-Rad President and Chief Executive Officer. "His many years of experience across life science and healthcare and will be a valuable addition to Bio-Rad."
Mr. McComb holds a Bachelor of Science degree in genetics from University of California, Davis and a Master of Business Administration degree from Golden Gate University.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.